Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 7/20 | 0.37 |
| ▸ | BCHE | P06276 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248347 | 0.85 | CHRM2 (0.52) | CHRM2CHRM1CHRM3GRIN2BACHE | |
| SCHEMBL4245972 | 0.83 | GRIN2B (0.40) | GRIN2BACHEBCHEMAOB | |
| SCHEMBL4238211 | 0.81 | CHRM2 (0.47) | CHRM2CHRM1CHRM3ACHEBCHE | |
| SCHEMBL4241506 | 0.81 | CHRM2 (0.48) | CHRM2CHRM1CHRM3ACHEBCHE | |
| SCHEMBL4240894 | 0.79 | CHRM2 (0.47) | CHRM2CHRM1CHRM3GRIN2BACHE | |
| SCHEMBL4248182 | 0.78 | ACHE (0.48) | ACHEBCHEPKMMAOB | |
| SCHEMBL4237271 | 0.78 | CHRM2 (0.46) | CHRM2CHRM1CHRM3ACHEBCHE | |
| SCHEMBL4237321 | 0.78 | SIGMAR1 (0.44) | CHRM2CHRM1CHRM3GRIN2BACHE | |
| SCHEMBL4244214 | 0.78 | KCNH2 (0.45) | CHRM2CHRM1CHRM3ACHEBCHE | |
| SCHEMBL4250571 | 0.77 | CHRM2 (0.52) | CHRM2CHRM1CHRM3ACHEOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | CHRM2 2/4885CHRM1 5/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.